Table 2.
Rate ratios (RR) with 95% CIs for overall cancer and major cancer sites for male workers in the job categories in the upstream petroleum industry versus referents from the general working population of Norway, 1981–2003, adjusted for age at inclusion in the cohort, year of first exposure and education using the Cox proportional hazards model
| Referents (N[283002) |
Offshore workers combined (N[24765) |
Upstream operators (N[5853) |
Oil drilling (N[6722) |
Catering personnel (N[1231) |
Others offshore (N[10959) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD-10 | Site of cancer | n | n | RR (95% CI) | n | RR (95% CI) | n | RR (95% CI) | n | RR (95% CI) | n | RR (95% CI) |
| Overall cancer (all sites) | 8639 | 710 | 1.0 (0.9 to 1.1) | 225 | 0.9 (0.8 to 1.1) | 141 | 1.0 (0.8 to 1.1) | 58 | 1.1 (0.8 to 1.4) | 286 | 1.1 (1.0 to 1.2) | |
| C00–C14 | Lip, oral cavity and pharynx | 269 | 23 | 1.0 (0.6 to 1.5) | 5 | 0.7 (0.3 to 1.7) | 6 | 1.2 (0.6 to 2.8) | 6 | 3.5 (1.5 to 7.9)* | 6 | 0.6 (0.2 to 1.4) |
| C15 | Oesophagus | 62 | 12 | 2.6 (1.4 to 4.8)* | 4 | 2.8 (1.0 to 7.8)* | 2 | 2.1 (0.5 to 8.6) | 1 | 2.1 (0.3 to 15.3) | 5 | 2.7 (1.1 to 6.9)* |
| Adenocarcinoma | 22 | 5 | 2.7 (1.0 to 7.0)* | 3 | 4.3 (1.3 to 14.5)* | 0 | — | 0 | — | 2 | 3.2 (0.8 to 13.9) | |
| Squamous cell carcinoma | 34 | 5 | 2.2 (0.8 to 5.6) | 1 | 1.8 (0.2 to 13.1) | 1 | 2.4 (0.3 to 17.4) | 1 | 4.2 (0.6 to 31.3) | 2 | 1.9 (0.4 to 7.8) | |
| C16 | Stomach | 266 | 23 | 1.0 (0.7 to 1.6) | 8 | 0.9 (0.4 to 2.0) | 6 | 1.6 (0.7 to 3.5) | 2 | 1.1 (0.3 to 4.5) | 7 | 0.9 (0.4 to 1.8) |
| C18–C21 | Colon, rectum and anus | 1120 | 71 | 0.8 (0.6 to 1.0)* | 23 | 0.8 (0.5 to 1.1) | 10 | 0.5 (0.3 to 1.0) | 5 | 0.6 (0.2 to 1.5) | 33 | 1.0 (0.7 to 1.4) |
| C25 | Pancreas | 186 | 8 | 0.6 (0.3 to 1.1) | 3 | 0.6 (0.2 to 2.0) | 2 | 0.8 (0.2 to 3.1) | 1 | 0.8 (0.1 to 5.9) | 2 | 0.4 (0.1 to 1.4) |
| C32 | Larynx | 90 | 16 | 2.3 (1.4 to 4.0)* | 4 | 1.7 (0.6 to 4.7) | 1 | 0.7 (0.1 to 5.3) | 2 | 3.0 (0.7 to 12.4) | 9 | 3.7 (1.8 to 7.3)* |
| C33–34 | Lung, bronchus and trachea | 892 | 92 | 1.3 (1.0 to 1.6)* | 31 | 1.3 (0.9 to 2.0) | 12 | 0.9 (0.5 to 1.5) | 8 | 1.3 (0.6 to 2.5) | 41 | 1.5 (1.1 to 2.0)* |
| C43 | Malignant melanoma (skin) | 808 | 61 | 0.9 (0.7 to 1.1) | 20 | 0.8 (0.5 to 1.2) | 16 | 1.1 (0.7 to 1.8) | 5 | 1.2 (0.5 to 2.8) | 20 | 0.8 (0.5 to 1.2) |
| C45 | Mesothelioma | 45 | 4 | 1.2 (0.4 to 3.4) | 1 | 1.0 (0.1 to 7.1) | 0 | — | 0 | — | 3 | 2.2 (0.7 to 7.2) |
| C61 | Prostate | 1377 | 110 | 1.1 (0.9 to 1.3) | 31 | 1.0 (0.7 to 1.4) | 22 | 1.1 (0.7 to 1.7) | 3 | 0.3 (0.1 to 1.0) | 54 | 1.4 (1.1 to 1.8)* |
| C62 | Testis | 537 | 51 | 1.1 (0.8 to 1.4) | 19 | 1.6 (1.0 to 2.5) | 8 | 0.6 (0.3 to 1.3) | 5 | 1.9 (0.8 to 4.5) | 19 | 1.0 (0.6 to 1.5) |
| C64 | Kidney | 264 | 29 | 1.3 (0.8 to 1.9) | 8 | 0.92 (0.4 to 2.0) | 6 | 1.1 (0.5 to 2.7) | 3 | 1.7 (0.6 to 5.4) | 12 | 1.6 (0.9 to 2.8) |
| C67 | Bladder | 457 | 41 | 1.1 (0.8 to 1.6) | 9 | 0.74 (0.4 to 1.4) | 8 | 1.2 (0.6 to 2.4) | 6 | 1.7 (0.7 to 4.2) | 18 | 1.3 (0.8 to 2.2) |
| C70–C72 | Central nervous system | 477 | 34 | 0.8 (0.6 to 1.2) | 9 | 0.7 (0.4 to 1.3) | 8 | 0.9 (0.4 to 1.8) | 3 | 1.1 (0.4 to 3.5) | 14 | 0.9 (0.5 to 1.5) |
| C91–C95 | Leukaemia | 188 | 18 | 1.1 (0.7 to 1.9) | 11 | 2.1 (1.1 to 3.8)* | 4 | 1.2 (0.4 to 3.2) | 0 | — | 3 | 0.5 (0.2 to 1.6) |
| C90 | Multiple myeloma | 124 | 17 | 1.7 (1.0 to 2.9)* | 10 | 2.6 (1.3 to 5.1)* | 3 | 1.7 (0.5 to 5.3) | 2 | 2.3 (0.6 to 9.5) | 2 | 0.6 (0.2 to 2.5) |
| C81 | Hodgkin lymphoma | 85 | 4 | 0.5 (0.2 to 1.4) | 0 | — | 2 | 1.0 (0.2 to 4.0) | 0 | — | 2 | 0.6 (0.2 to 2.6) |
| C82–85, C96 | Non-Hodgkin lymphoma | 448 | 27 | 0.7 (0.5 to 1.0) | 11 | 0.8 (0.4 to 1.5) | 5 | 0.6 (0.3 to 1.5) | 1 | 0.4 (0.1 to 2.6) | 10 | 0.7 (0.4 to 1.3) |
The letter ‘n’ denotes number of cases.
*
Statistically significant.